EVENTS | VIEW CALENDAR
LabCorp division partners with DHMRI to offer enhanced assay development services
BURLINGTON, N.C.—Esoterix Clinical Trials Services, a division of Laboratory Corporation of America Holdings, recently entered into an alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services.
Under the companies' arrangement, assays developed at DHMRI for contracted research will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.
LabCorp offers a broad test menu ranging from routine blood analyses to reproductive genetics to DNA sequencing. The company's clients include physicians, government agencies, managed care organizations, hospitals, clinical labs and pharmaceutical companies.
The services available to clients through DHMRI include broad biomarker discovery and proof-of-concept assay development to support early- and late-stage drug discovery and development. DHMRI uses transdisciplinary approaches to provide solutions for customers. DHMRI has capabilities and expertise ranging from profiling at the genetic, biochemical, cellular and in-vivo levels to clinical immune system monitoring using multiparameter flow cytometry and multiplexed protein analysis and quantitative gene expression.
"With the addition of DHMRI's discovery capabilities, LabCorp offers its clinical trials clients the most complete suite of biomarker development tools in the industry," said Dr. David Johnston, senior vice president and global head of clinical trials at LabCorp, in a statement. "Our collaboration with DHMRI exemplifies our strong commitment to providing cutting-edge services to our clients."